Lycera Raises $36 Million

Lycera Corp., an Ann Arbor, Mich.-based drug developer focused on autoimmune diseases, has raised $36 million in Series A funding. The deal is tranched-out based on milestones, with Lycera already having called down the first $10 million. InterWest Partners, ARCH Venture Partners and Clarus Ventures co-led the round, with seed backer EDF Ventures also participating.

North AmericaUSBriefs